69 related articles for article (PubMed ID: 3171176)
1. Mutant monoclonal antibodies with select alteration in complement activation ability. Impact on immune complex functions in vivo.
Nose M; Okuda T; Gidlund M; Ramstedt U; Okada N; Okada H; Heyman B; Kyogoku M; Wigzell H
J Immunol; 1988 Oct; 141(7):2367-73. PubMed ID: 3171176
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors.
Baiu DC; Prechl J; Tchorbanov A; Molina HD; Erdei A; Sulica A; Capel PJ; Hazenbos WL
J Immunol; 1999 Mar; 162(6):3125-30. PubMed ID: 10092761
[TBL] [Abstract][Full Text] [Related]
3. Relationship between complement activation and renal deposition of immune complexes made with IgG2a monoclonal antibodies.
Gonzalez ML; Waxman FJ
Clin Immunol; 2001 Sep; 100(3):362-71. PubMed ID: 11513550
[TBL] [Abstract][Full Text] [Related]
4. Experimental glomerulonephritis induced by immune complexes of monoclonal antibodies produced by immunoglobulin class-switch variants.
Chen XM; Tanaka T; Kobayashi Y; Shigematsu H; Okumura K
Lab Invest; 1987 Dec; 57(6):665-72. PubMed ID: 3695412
[TBL] [Abstract][Full Text] [Related]
5. Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies.
Rajnavölgyi E; Fazekas G; Lund J; Daeron M; Teillaud JL; Jefferis R; Fridman WH; Gergely J
Immunology; 1995 Apr; 84(4):645-52. PubMed ID: 7540592
[TBL] [Abstract][Full Text] [Related]
6. Complement activation is not required for IgG-mediated suppression of the antibody response.
Heyman B; Wiersma E; Nose M
Eur J Immunol; 1988 Nov; 18(11):1739-43. PubMed ID: 3060362
[TBL] [Abstract][Full Text] [Related]
7. Phagocytosis by mouse peritoneal macrophages plated on monoclonal antibody-coated immune complex-substrates: effects of complexes of different IgG subclasses on Fc receptor functions.
Sung SS
J Immunol; 1985 Sep; 135(3):1981-6. PubMed ID: 4020136
[TBL] [Abstract][Full Text] [Related]
8. The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes.
Kurlander RJ; Ellison DM; Hall J
J Immunol; 1984 Aug; 133(2):855-62. PubMed ID: 6736648
[TBL] [Abstract][Full Text] [Related]
9. IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice.
Wernersson S; Karlsson MC; Dahlström J; Mattsson R; Verbeek JS; Heyman B
J Immunol; 1999 Jul; 163(2):618-22. PubMed ID: 10395649
[TBL] [Abstract][Full Text] [Related]
10. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
11. Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16).
Hazenbos WL; Heijnen IA; Meyer D; Hofhuis FM; Renardel de Lavalette CR; Schmidt RE; Capel PJ; van de Winkel JG; Gessner JE; van den Berg TK; Verbeek JS
J Immunol; 1998 Sep; 161(6):3026-32. PubMed ID: 9743367
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
13. [Interaction of immune complexes and their leukocyte receptors: regulation by the complement system and by cyclophosphamide].
Isturiz MA; Giordano M; Geffner JR; Palermo MS; Serebrinsky G
Medicina (B Aires); 1989; 49(2):140-6. PubMed ID: 2640483
[TBL] [Abstract][Full Text] [Related]
14. Immune adherence and staphylococcus protein A binding of soluble immune complexes produced by complement activation.
Schifferli JA; Peters DK
Clin Exp Immunol; 1983 Dec; 54(3):827-33. PubMed ID: 6228359
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
16. The role of mesangial complement in the hematuria of experimental IgA nephropathy.
Emancipator SN; Ovary Z; Lamm ME
Lab Invest; 1987 Sep; 57(3):269-76. PubMed ID: 3306149
[TBL] [Abstract][Full Text] [Related]
17. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
18. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal anti-mouse macrophage antibodies recognize the globular portions of C1q, a subcomponent of the first component of complement.
Heinz HP; Dlugonska H; Rüde E; Loos M
J Immunol; 1984 Jul; 133(1):400-4. PubMed ID: 6609989
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
